1887

Abstract

Sitafloxacin (SFX) is a new fluoroquinolone (FQ) that has shown a strong bactericidal effect against (Mtb) . However, data on SFX efficacy against Mtb with mutations and its epidemiological cut-off (ECOFF) value remain limited. Therefore, we evaluated and compared the activity of SFX against -mutant Mtb to that of moxifloxacin (MFX), levofloxacin (LFX) and ciprofloxacin (CFX), and determined the ECOFF for SFX.

A total of 109 clinical Mtb isolates, including 73 multidrug-resistant (MDR) isolates, were subjected to minimum inhibitory concentration (MIC) analysis in oleic-albumin-dextrose-catalase (OADC)-supplemented Middlebrook 7H9 medium. Our results showed that SFX had lower cumulative MIC than MFX, LFX and CFX. Furthermore, we performed direct DNA sequencing of the quinolone-resistance-determining regions (QRDRs).

We identified the following mutations: D94G, D94A, A90V, D94H, D94N and G88A in gyrA; and A543V, A543T, E540D, R485C, D500A, I552S and D577A in . Based on our results, an ECOFF of 0.125 µg ml was proposed for SFX. With this ECOFF, 15 % of LFX-resistant isolates with MIC ≥2 µg ml were susceptible to SFX.

SFX had the lowest cumulative MIC and a relatively low ECOFF value against Mtb, indicating that SFX was not only more effective against -mutant isolates, but also MDR isolates in Japan.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000493
2017-06-01
2020-01-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/6/770.html?itemId=/content/journal/jmm/10.1099/jmm.0.000493&mimeType=html&fmt=ahah

References

  1. World Health Organization 2016; Global tuberculosis report. www.who.int/tb/en [accessed 24 February 2017]
  2. World Health Organization 2016; WHO treatment guidelines for drug-resistant tuberculosis. www.who.int/tb/MDRTBguideline2016.pdf [accessed 24 February 2017]
  3. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009;13:79–83[PubMed]
    [Google Scholar]
  4. Ahmad N, Javaid A, Sulaiman SA, Ming LC, Ahmad I et al. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis 2016;20:41–47 [CrossRef][PubMed]
    [Google Scholar]
  5. Tuberculosis Research Committee (RYOKEN), Tokyo, Japan Nationwide survey of anti-tuberculosis drug resistance in Japan. Int J Tuberc Lung Dis 2015;19:157–162 [CrossRef][PubMed]
    [Google Scholar]
  6. Ando H, Mitarai S, Kondo Y, Suetake T, Kato S et al. Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol 2011;60:184–188 [CrossRef][PubMed]
    [Google Scholar]
  7. Keating GM. Sitafloxacin: in bacterial infections. Drugs 2011;71:731–744 [CrossRef][PubMed]
    [Google Scholar]
  8. Disratthakit A, Doi N. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob Agents Chemother 2010;54:2684–2686 [CrossRef][PubMed]
    [Google Scholar]
  9. Disratthakit A, Prammananan T, Tribuddharat C, Thaipisuttikul I, Doi N et al. Role of gyrB mutations in pre-extensively and extensively drug-resistant tuberculosis in Thai clinical isolates. Antimicrob Agents Chemother 2016;60:5189–5197 [CrossRef][PubMed]
    [Google Scholar]
  10. Suzuki Y, Nakajima C, Tamaru A, Kim H, Matsuba T et al. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. Int J Antimicrob Agents 2012;39:435–439 [CrossRef][PubMed]
    [Google Scholar]
  11. Chikamatsu K, Aono A, Yamada H, Sugamoto T, Kato T et al. Comparative evaluation of three immunochromatographic identification tests for culture confirmation of Mycobacterium tuberculosis complex. BMC Infect Dis 2014;14:54 [CrossRef][PubMed]
    [Google Scholar]
  12. Coban AY, Birinci A, Ekinci B, Durupinar B. Drug susceptibility testing of Mycobacterium tuberculosis by the broth microdilution method with 7H9 broth. Mem Inst Oswaldo Cruz 2004;99:111–113 [CrossRef][PubMed]
    [Google Scholar]
  13. Otsuka Y, Parniewski P, Zwolska Z, Kai M, Fujino T et al. Characterization of a trinucleotide repeat sequence (CGG)5 and potential use in restriction fragment length polymorphism typing of Mycobacterium tuberculosis. J Clin Microbiol 2004;42:3538–3548 [CrossRef][PubMed]
    [Google Scholar]
  14. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopeć E, Zwolska Z, Kirikae F et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2007;45:179–192 [CrossRef][PubMed]
    [Google Scholar]
  15. Dauendorffer JN, Guillemin I, Aubry A, Truffot-Pernot C, Sougakoff W et al. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J Clin Microbiol 2003;41:1311–1315 [CrossRef][PubMed]
    [Google Scholar]
  16. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012;67:819–831 [CrossRef][PubMed]
    [Google Scholar]
  17. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S et al. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 2012;56:1990–1996 [CrossRef][PubMed]
    [Google Scholar]
  18. Kahlmeter G. The 2014 Garrod Lecture: EUCAST – are we heading towards international agreement?. J Antimicrob Chemother 2015;70:2427–2439 [CrossRef][PubMed]
    [Google Scholar]
  19. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY et al. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol 2013;62:108–113 [CrossRef][PubMed]
    [Google Scholar]
  20. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 2014;58:364–369 [CrossRef][PubMed]
    [Google Scholar]
  21. World Health Organization 2010; Treatment of tuberculosis guidelines, 4th ed. www.who.int/tb/publications/tb_treatmentguidelines/en [accessed 24 February 2017]
  22. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S et al. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999;43:3001–3004[PubMed]
    [Google Scholar]
  23. Kang YA, Shim TS, Koh WJ, Lee SH, Lee CH et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc 2016;13:364–370 [CrossRef][PubMed]
    [Google Scholar]
  24. Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010;65:946–952 [CrossRef][PubMed]
    [Google Scholar]
  25. World Health Organization 2014; Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. www.who.int/tb/publications/pmdt_companionhandbook/en [accessed 24 February 2017]
  26. Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrAse as a target for drug discovery. Infect Disord Drug Targets 2007;7:159–168 [CrossRef][PubMed]
    [Google Scholar]
  27. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773–780 [CrossRef][PubMed]
    [Google Scholar]
  28. Coeck N, de Jong BC, Diels M, de Rijk P, Ardizzoni E et al. Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis. J Antimicrob Chemother 2016;71:1233–1240 [CrossRef][PubMed]
    [Google Scholar]
  29. Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One 2015;10:e0120470 [CrossRef][PubMed]
    [Google Scholar]
  30. Kim H, Nakajima C, Yokoyama K, Rahim Z, Kim YU et al. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob Agents Chemother 2011;55:3661–3667 [CrossRef][PubMed]
    [Google Scholar]
  31. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A et al. Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis. J Clin Microbiol 2016;54:727–733 [CrossRef][PubMed]
    [Google Scholar]
  32. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012;67:819–831 [CrossRef][PubMed]
    [Google Scholar]
  33. Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A et al. Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis 2015;95:137–141 [CrossRef][PubMed]
    [Google Scholar]
  34. Chien JY, Chiu WY, Chien ST, Chiang CJ, Yu CJ et al. Mutations in gyrA and gyrB among fluoroquinolone- and multidrug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2016;60:2090–2096 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000493
Loading
/content/journal/jmm/10.1099/jmm.0.000493
Loading

Data & Media loading...

Supplements

Supplementary File 1

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error